---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006139"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T12:25:39.692660+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Heron launches APONVIE IV for PONV prevention; cites 50% fewer vomiting vs ondansetron

## Summary
- APONVIE (aprepitant injectable emulsion) is first IV NK1 receptor antagonist for postoperative nausea and vomiting (PONV).
- Single IV push achieves ≥97% brain receptor occupancy within 5 minutes and maintains therapeutic levels for 48 hours.
- Aprepitant reduced vomiting by ~50% in first 24 and 48 hours vs IV ondansetron in clinical trials.
- Target market: ~36 million U.S. procedures annually in high/moderate PONV risk patients; CEO sees potential for several hundred million dollars in sales.
- Launch leverages existing acute-care commercial team with no additional field force or significant external spend.

## SEC filing metadata
- accession: 0000950170-23-006139
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023006139/0000950170-23-006139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023006139/hrtx-20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006139
- JSON: https://secwatch.observer/filing/0000950170-23-006139.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.